EU Offers €80 Million Loan To German Vaccine Pharma

Politico Europe reports:

Brussels has entered into an ill-tempered diplomatic skirmish between Germany and the U.S. over a company that is developing a vaccine against coronavirus.

CureVac, a company based in the German town of Tübingen, hit the headlines over the weekend when Germany’s Welt am Sonntag newspaper reported that U.S. President Donald Trump was attempting to snatch up exclusive rights to the business’s coronavirus vaccine, developed in cooperation with a publicly funded German institute.

While the report has pitched U.S. and German officials into a war of words, the European Commission said Monday it would offer the company a guaranteed loan worth €80 million “to scale up development and production of a vaccine against the coronavirus in Europe.”